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Myocardial infarctionCoronary Slow Flow Phenomenon (CSFP) is an angiographic phenomenon in which vessel opaciﬁcation is de-
layedwithout any evidence of obstructive epicardial coronary disease.We aim to present, in this paper, extreme-
ly slow coronary ﬂowalongwith its severe clinicalmanifestation. A 47-year-oldmale patientwas admitted to our
emergency department with ST elevation myocardial infarction caused by coronary slow ﬂow. Oral
Acetylsalicylic acid, nebivolol and atorvastatin therapy successfully resulted in complete resolution of his symp-
toms during the 18-month observation.
© 2015 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The Coronary Slow Flow Phenomenon (CSFP), an angiographic phe-
nomenon ﬁrst described by Tambe et al. in 1972, refers to the slow
movement of contrast agents in the coronary arteries without signiﬁ-
cant stenosis ormyocardial bridge.1 The Thrombolysis inMyocardial In-
farction (TIMI) frame count, a reproducible index of coronary ﬂow,
functions as the quantitative measurement of coronary slow ﬂow.2
More speciﬁcally, it is a numerical representation of cine frames which
are necessary for the contrast agents to reach a pre-speciﬁed distal cor-
onary artery landmark. The process is continuous with a correction
through normalization of the left anterior descending artery (LAD).
The corrected TIMI frame count (CTFC) is the division of the absolute
TIMI frame count in the LAD by 1.7. The CSFP phenomenon is character-
ized by CTFC N2 standard deviations from normal published range
(21±3).2 It has been reported that 1–5.5%of patientswhoundergo cor-
onary angiography experience CSFP.3 However, the pathophysiology of
CSFP has not been comprehensively discerned. In this paper, we present
a rare case of STEMI caused by coronary slow ﬂow, whichmight help us
to understand better the CSFP.Case
A47-year-oldmanwho complained of chest pain spreading towards
his shoulder, the pain having begun nearly an hour prior, was admitted
into our emergency department. His blood pressure was 110/partment of Cardiology, 43000,
316673.
).
ascular Academy.
my. Production and hosting by Else75 mm Hg, his heart rate was 52 beats/min, and his cardiopulmonary
examination was normal. His electrocardiogram showed ST elevation
in leads V1–4 (Fig. 1A). Then, he was immediately taken to the labora-
tory for coronary angiography. There was no signiﬁcant stenosis, coro-
nary vasospasm or myocardial bridge in coronary angiography.
Further, intracoronary nitro-glycerine fusion was performed to exclude
vasospastic angina. However, no change in ST elevation was observed.
On the other hand, advanced-degree slow ﬂow was observed in the
LAD and right coronary artery (RCA). The TIMI frame-count method
was used to measure the degree of slow ﬂow. The CTFCs were observed
to be 52 frames for the left anterior descending coronary artery (Fig. 2A)
and 35 frames for the RCA (Fig. 2B). After about 30 min, the patient's
chest pain had disappeared completely; ST elevation improved
(Fig. 1B); and Troponin I was slightly elevated (Troponin I 0.24 μg/L
(normal range, 0.010–0.023 μg/L)). In terms of lipid proﬁle, the ﬁndings
were as follows: total cholesterol: 182 mg/dL, LDL: 109 mg/dL, HDL: 35
mg/dL, and TG: 192 mg/dL. Other biochemical values were normal, his
body mass index was in the normal range, and there were no cardiac
risk factors other than smoking. Two-dimensional echocardiography
showed normal left ventricle function and no wall motion abnormali-
ties. Acetylsalicylic acid 300 mg, nebivolol 5 mg and atorvastatin
20 mg were started. The patient was discharged without chest pain
after four days with a prescription of acetylsalicylic acid 100 mg,
nebivolol 5 mg and atorvastatin 20mg. There was no complaint report-
ed during the 18-month period after discharge.
Discussion
Recurrent chest pain is a commonly observed symptom among
patients with CSFP.4 Although it is rare, CSFP may also lead to life-
threatening situations such as ST elevation myocardial infarctionvier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. The electrocardiogram shows ST elevation in leads V1–4 during presence of chest pain (A). ST elevation improved after disappearance of chest pain (B).
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Recently, a patient presented as having acute coronary syndrome re-
portedly illustrated an association between CSFP and a new onset of in-
termittent left bundle branch block (LBBB).11 Also, Sunbul et al.12
suggested that slow coronary ﬂow might lead to ST segment elevation
in the exercise stress test.
Although different theories have been posited regarding the causes
of CSFP, research has not been able to discern comprehensively its path-
ogenesis. In a variety of researches, small vessel disease, endothelial
dysfunction, subclinical atherosclerosis, inﬂammation, and anatomic
properties of coronary arteries have been reported as existing in associ-
ation with CSFP. Among these, small vessel dysfunction is one of the
most typical of the pathogenesis of CSFP.13 In an effort to conﬁrm this
hypothesis, Beltrame et al. suggested that ﬁbromuscular hyperplasia,
medial hypertrophy, myointimal proliferation, endothelial edema, and
the thickening aswell as the degeneration of the coronarymicro-vessels
correspond with the phenomenon.14 Therefore, it is perhaps more
ﬁtting to suggest that the coronary microcirculation might be a result
of the coexistence of structural and functional abnormalities. In a
variety of cases, patients with CSFP were reported to have increased
levels of plasma homocysteine, increased endothelin-1 release and
reduced nitric oxide bioactivity, which indicated impaired endothelial
function.3,15–18 CSFP patients have metabolic syndrome more
frequently.19 As a result of the use of IVUS technique and ﬂow ratemea-
surements, diffuse intimal thickening, widespread calciﬁcation along
the coronary vessel wall, and non-obstructive atheromatous coronarychanges were reported among patients with CSFP.20 Based on the data
presented here, it can be argued that CSFP might reﬂect diffuse, non-
obstructive atherosclerotic disease of epicardial vessels together with
microvascular disease. Moreover, elevated plasma concentration of
high-sensitivity C-reactive protein and interleukin-6 were documented
among CSFP patients.21 In a similar vein, higher levels of plasma-soluble
adhesion molecules such as intercellular adhesion molecule-1, vascular
cell adhesion molecule-1 and E-selectin were reported to exist in rela-
tion to coronary slow ﬂow.22 Red cell distribution width and serum
uric acid levels, among other inﬂammatorymarkers, were studied in as-
sociation with CSFP patients.23,24 In endothelial dysfunction, abnormal-
ities in inﬂammatory parameters can possibly be an indicator; both of
these contribute to coronary slow ﬂow. Shao-Ping et al.25 demonstrated
the existence of CSFP in relation to higher tortuosity and more distal
branches in coronary arteries. Thus, certain anatomic properties of cor-
onary arteries could be alleged to have an effect on disturbed coronary
ﬂow and endothelial damage, therefore resulting in CSFP.
Treatment for CSFP has not yet been clearly deﬁned, but several
drugs have proven to be effective at various levels. So far, pharmacolog-
ical therapy for CSFP has not been executed on a large scale. Certain
small studies have presented evidence regarding the drugs. In some
studies, dipyridamole, mibefradil and nitroglycerine have been used
for the treatment of CSFP.19,26 Statins present certain beneﬁts for CSFP
patients, partially owing to their anti-inﬂammatory properties.27
Nebivolol not only can improve endothelial function but also can
remedy symptoms considerably; therefore, the drug enhances the
Fig. 2. Coronary angiogram reveals no signiﬁcant stenosis, together with coronary slow ﬂow in LAD (A) and RCA (B).
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beta-receptor blocker and, due to increased nitric oxide release, result
in endothelium-dependent vasodilatation.28
Conclusion
Slow ﬂowmight sound like aminor condition; however, it can result
in such a fatal condition as STEMI. With proper treatment, on the other
hand, symptoms are reduced. In conclusion, we recommend that CSFP
be considered in the etiology of chest pain with ST elevation.
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